Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retifanlimab - Incyte Corporation/MacroGenics

Next Previous
X
Search
Drug Profile

Retifanlimab - Incyte Corporation/MacroGenics

Alternative Names: AEX-1188; INCMGA-0012; INCMGA00012; MGA-012; Retifanlimab-dlwr; Zynyz

Latest Information Update: 06 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Developer BriaCell Therapeutics Corp; Incyte Corporation; MacroGenics; University of Washington; ZAI Lab
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anal cancer; Merkel cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Merkel cell carcinoma
  • Preregistration Squamous cell cancer
  • Phase III Endometrial cancer; Non-small cell lung cancer
  • Phase II/III Gastric cancer; Oesophageal cancer
  • Phase II Adenosquamous carcinoma; Bladder cancer; Glioblastoma; Glioma; Head and neck cancer; Liposarcoma; Pancreatic cancer; Penile cancer; Sarcoma; Solid tumours; Triple negative breast cancer
  • Phase I/II Breast cancer; Colorectal cancer; Malignant melanoma; Soft tissue sarcoma
  • Phase I Adenocarcinoma
  • No development reported Acute myeloid leukaemia; Haematological malignancies

Most Recent Events

  • 30 Jul 2024 Efficacy and adverse events data from the POD1UM-303 phase III trial in Squamous cell cancer released by Incyte
  • 30 Jul 2024 Efficacy and adverse events data from the POD1UM-304 phase III trial in Non-small cell lung cancer released by Incyte
  • 22 May 2024 Incyte completes a phase I trial in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in United Kingdom, Ukraine, Spain, Poland, New Zealand, Lithuania, Latvia, Italy, Germany, France, Finland, China, Bulgaria, Belgium, Australia, USA (IV) (NCT03059823)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top